|Articles|August 15, 2002
- BioPharm International-08-01-2002
- Volume 15
- Issue 8
Survival Guide to FDA Inspections: Part 1, To Prepare or Not to Prepare, There Is No Question
Author(s)Massoud Lavian, Paul W. Allen
by Massoud Lavian and Paul W. Allen, Clarkston Consulting Would your company survive a surprise inspection? An FDA inspection can be a nightmare that costs your company money, time, and reputation. Proactive managers understand the logic behind FDA regulations and prepare accordingly. This three-part survival guide to inspections (whether from FDA, a client, an investor, or a European agency) will sharpen your vision of your company?s regulatory compliance picture.
Advertisement
Articles in this issue
over 23 years ago
Guest Editorial: Quality Agreements with Contract Laboratoriesover 23 years ago
Your Vested Interests: Gorillas In Our MidstNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
HHS Releases New Guidance on Lowering Prescription Drug Prices Through DTC Programs
2
Industrial-Scale Cell Therapy Automation Gains Traction with New Cellares Funding
3
AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint
4
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
5
